General Hospital of Ningxia Medical University
The purpose of this study is to investigate the efficacy of intravenous lidocaine on THBS2, MMPs and VEGF-C in serum in cervical cancer patients undergoing radical hysterectomy under general anesthesia.
Cervical Cancer
Metastatic Cancer
Lidocaine
Normal saline (NS)
Not Applicable
The surgical stress response to tumour removal causes bloodstream release of a variety of pro-inflammatory cytokines and other molecules which may affect perioperative immune response and other conditions conducive to residual tumour cell survival that could later emerge as clinical recurrences or metastasis. Lidocaine has analgesic and anti-inflammatory effects, and may also have specific anticancer properties. Blood serum expression of these molecules (metalloproteinases, vascular endothelial growth factor [VEGF], epidermal growth factor）, play a important role in the metastatic process and tumor progression. lidocaine could affect the course and growth of metastatic tumors by changing the cancer cells, the tumor microenvironment, or both. We tested the hypothesis that women undergoing cervical cancer resection with these techniques (intravenous lidocaine) have reduced postoperative serum expression of metastasis biomarkers, and may change the outcomes of cancer patients.}}
| Study Type : | Interventional |
| Estimated Enrollment : | 60 participants |
| Masking : | Double |
| Primary Purpose : | Prevention |
| Official Title : | Effects of Intravenous Lidocaine on Serum THBS2, MMPS and VEGF-C in Patients Undergoing Radical Hyterectomy Surgery After General Anesthesia |
| Actual Study Start Date : | December 1, 2022 |
| Estimated Primary Completion Date : | July 1, 2024 |
| Estimated Study Completion Date : | December 1, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Lidocaine Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h. |
Drug: Lidocaine |
|
Placebo Comparator: Normal saline Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group. |
Other: Normal saline (NS) |
| Ages Eligible for Study: | 18 Years to 65 Years |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.